Brain Health & Nootropics
Semax
← Back to Library
Limited / unverified FDA safety flag Limited / unverified Neural Stimulant
Educational reference only. Read the full disclaimer.
The protocols below are not automatically an FDA-approved or clinically verified regimen unless
explicitly marked as label-verified or clinical-trial above.
Overview
Route(s): Subcutaneous
Typical vial sizes: 10, 30 mg
Dosing window: Morning
Receptor / target: TrkB; MC4R
Properties: Neural Stimulant
Pre-mixed: No
Unverified protocol notes
Standard Protocol
| Timeframe | Dose | Notes |
|---|---|---|
| Weeks 1-6 | 100mcg to 300mcg daily | Administered subQ in the morning. Effects are usually immediate. |
Unverified protocol note; not label dosing unless graded otherwise on this page.
Alternative: Acute Recovery
| Timeframe | Dose | Notes |
|---|---|---|
| Weeks 1-2 | 500mcg to 1,000mcg daily | High-dose protocol utilized clinically for acute stroke recovery or severe cognitive decline. |
| Weeks 3-4 | 300mcg daily | Step down to maintenance. |
Unverified alternative protocol; not an approved-label regimen unless graded otherwise on this page.
Protocol logic check
Protocol context: Nootropic protocols are state-dependent: sleep, anxiety, stimulants, psychiatric history, and route can change the response. The logic is morning-biased, low-entry dosing, and stopping if arousal or mood destabilizes. Entry context: target (TrkB; MC4R); route Subcutaneous; timing Morning. Limited-evidence dosing tables are hypotheses, not recommendations. FDA/safety flags lower confidence and raise the evidence bar for any claimed benefit. Compatibility is conditional: a reasonable solo compound can become inappropriate once a contraindicated partner is added.
Independent evidence
Independent safety notes: FDA lists semax with immunogenicity/impurity concerns and limited safety information.
Regulatory status: unapproved or compounded peptide with FDA safety risk flag
Storage
No independently verified storage guidance found. Treat any unverified storage claim as unverified, and see the general storage guidance in the FAQ.
Contraindications (limited evidence)
- Concurrent Adamax use: Adamax is a potentiated derivative of Semax sharing the same TrkB/MC4R/BDNF mechanism; co-administration produces redundant receptor overstimulation without additional therapeutic benefit and significantly increases anxiety, cardiovascular stimulation, and insomnia risk; these compounds are mutually exclusive and should never be used simultaneously. Limited / unverified
- Severe anxiety disorders, generalized anxiety disorder (GAD), or panic disorder: Semax's MC4R activation and dopaminergic enhancement can meaningfully worsen anxiety symptomatology in predisposed subjects; baseline anxiety must be well-controlled before initiating. Limited / unverified
- Active manic episode or bipolar I disorder during manic phase: Semax's stimulant-adjacent nootropic activity and dopaminergic enhancement can trigger or accelerate manic symptoms in susceptible individuals. Limited / unverified
- Active psychotic disorders (schizophrenia, schizoaffective disorder): MC4R and dopaminergic pathway stimulation is contraindicated during active psychosis. Limited / unverified
- Severe uncontrolled hypertension: Semax produces mild adrenergic activation as a secondary effect of MC4R agonism; not a primary cardiovascular concern but warrants caution in severely hypertensive subjects. Limited / unverified
- Known hypersensitivity to Semax or ACTH-derived peptides. Limited / unverified
- Pregnancy: no human safety data; ACTH-derived peptide activity during pregnancy is not established as safe. Limited / unverified
- Breastfeeding: insufficient safety data. Limited / unverified
- Concurrent use with MAOIs: additive dopaminergic and serotonergic potentiation creates serotonin syndrome risk. Limited / unverified
Side effects (limited evidence)
- Over-stimulation and irritability: the most commonly reported adverse effect; mild to moderate CNS stimulation, particularly with doses above 300mcg; characterized by restlessness, mild agitation, and shortened patience; typically dose-dependent and resolves with dose reduction. Limited / unverified
- Insomnia: MC4R activation increases arousal state; morning dosing is mandatory; any dose taken after noon risks sleep onset difficulty that evening. Limited / unverified
- Mild tachycardia: adrenergic-adjacent stimulation from MC4R activation produces a slight elevation in resting heart rate in some subjects; usually mild and transient. Limited / unverified
- Anxiety exacerbation: subjects with baseline anxiety disorders may experience worsening of anxiety symptoms; paradoxical given the BDNF/TrkB neuroprotective activity but consistent with the stimulant-like MC4R component. Limited / unverified
- Hair shedding (rare): BDNF elevation from Semax can accelerate hair follicle cycling, transiently shifting follicles from anagen (growth) into catagen/telogen (shedding) phase; typically reversible as BDNF normalizes post-cycle. Limited / unverified
- Mild headache: reported in initial days of use; may reflect cerebrovascular response to MC4R-driven changes in neurovascular tone. Limited / unverified
- Nasal irritation: relevant with intranasal formulations; not applicable to subcutaneous administration. Limited / unverified
- Appetite suppression: MC4R agonism in the hypothalamus has mild anorexigenic effects; generally not clinically significant at standard doses but notable in underweight individuals. Limited / unverified
- TrkB/MC4R receptor downregulation with prolonged continuous use: the mechanistic basis for the cycle/washout protocol; persistent receptor agonism without recovery periods reduces receptor density and diminishes subsequent cycle efficacy. Limited / unverified
Compatibility
The relationships below come from the source site's internal engine and were not verified independently. Treat them as a starting point for a conversation with a clinician. They carry no safety guarantee.
Reported synergistic:
Reported contraindicated combinations: